G-BA confirms Teva's Cinqaero gives minor additional benefit in severe asthma

The German Federal Joint Committee (G-BA) has determined that Teva Pharmaceuticals Europe's Cinqaero (reslizumab) provides minor additional benefit in certain asthma cases.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news